Xbrane Biopharma AB
F:7XB

Watchlist Manager
Xbrane Biopharma AB Logo
Xbrane Biopharma AB
F:7XB
Watchlist
Price: 1.037 EUR 10.26% Market Closed
Market Cap: 30.3m EUR
Section:
 

Relative Value

The Relative Value of one 7XB stock under the Base Case scenario is 18.712 EUR. Compared to the current market price of 1.037 EUR, Xbrane Biopharma AB is Undervalued by 94%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

7XB Relative Value
Base Case
18.712 EUR
Undervaluation 94%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.2
P/S
P/S
Price to Sales
1.2
vs History
82
vs Industry
78
Median 3Y
182.9
Median 5Y
253.1
Industry
8.2
Forward
1
More Details
2.5
P/E
P/E
Price to Earnings
2.5
vs History
6
vs Industry
Median 3Y
-116.6
Median 5Y
-918.3
Industry
24.2
Forward
99
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-225.2
Median 5Y
-930.8
Industry
23
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-167.4
Median 5Y
-767.2
Industry
25.5
More Details
0.4
P/B
P/B
Price to Book Value
0.4
vs History
96
vs Industry
44
Median 3Y
147.4
Median 5Y
543.4
Industry
3.3
More Details
0.7
EV/S
EV/S
Enterprise Value to Sales
0.7
vs History
82
vs Industry
69
Median 3Y
183.2
Median 5Y
253.3
Industry
8.6
Forward
0.6
More Details
1
EV/GP
EV/GP
Enterprise Value to Gross Profit
1
vs History
77
vs Industry
71
Median 3Y
286.7
Median 5Y
584.8
Industry
10.5
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
26
Median 3Y
-164.1
Median 5Y
-1 085.6
Industry
6.1
Forward
6.8
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
24
Median 3Y
-164.1
Median 5Y
-1 085.6
Industry
6.6
Forward
14.5
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
28
Median 3Y
-225
Median 5Y
-930.5
Industry
8.8
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
25
Median 3Y
-165.5
Median 5Y
-656.8
Industry
6.8
More Details
0.3
EV/IC
EV/IC
Enterprise Value to IC
0.3
vs History
96
vs Industry
61
Median 3Y
72.4
Median 5Y
434.1
Industry
5.7
More Details

Multiples Across Competitors

7XB Competitors Multiples
Xbrane Biopharma AB Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
Xbrane Biopharma AB
F:7XB
247.3m EUR 1.2 2.5 -4.4 -4.4
IL
Can Fite Biopharma Ltd
TASE:CANF
154.5T ILS 55 989 192 -3 844 977.4 -3 773 099.9 -3 764 701.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 067 817 -161 919.3 -196 621.7 -194 378
US
Abbvie Inc
NYSE:ABBV
391.8B USD 6.6 166.9 16.2 23
US
Amgen Inc
NASDAQ:AMGN
174.5B USD 4.9 24.9 18 18
US
Gilead Sciences Inc
NASDAQ:GILD
151.2B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.5B USD 9.9 31.4 23.1 24.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 067.9 -527.7 -574.6 -559.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.9B USD 5.6 17.5 16.6 18.9
AU
CSL Ltd
ASX:CSL
84B AUD 3.6 18.7 12.6 15.8
NL
argenx SE
XBRU:ARGX
42.7B EUR 13.8 32.4 55.7 57.2
P/S Multiple
Revenue Growth P/S to Growth
SE
Xbrane Biopharma AB
F:7XB
Average P/S: 8 187 193.4
1.2
38%
0
IL
C
Can Fite Biopharma Ltd
TASE:CANF
55 989 192
140%
399 922.8
FR
Pharnext SCA
OTC:PNEXF
34 067 817
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
2 067.9
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
6%
0.9
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
NL
argenx SE
XBRU:ARGX
13.8
49%
0.3
P/E Multiple
Earnings Growth PEG
SE
Xbrane Biopharma AB
F:7XB
Average P/E: 39.1
2.5
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 844 977.4 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 919.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
166.9
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.9
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.4
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
10%
1.7
AU
CSL Ltd
ASX:CSL
18.7
11%
1.7
NL
argenx SE
XBRU:ARGX
32.4
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SE
Xbrane Biopharma AB
F:7XB
Average EV/EBITDA: 22.1
Negative Multiple: -4.4 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 773 099.9 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 621.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.2
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
11%
1.5
AU
CSL Ltd
ASX:CSL
12.6
8%
1.6
NL
argenx SE
XBRU:ARGX
55.7
810%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SE
Xbrane Biopharma AB
F:7XB
Average EV/EBIT: 24.2
Negative Multiple: -4.4 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 764 701.1 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 378 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.1
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.9
13%
1.5
AU
CSL Ltd
ASX:CSL
15.8
11%
1.4
NL
argenx SE
XBRU:ARGX
57.2
N/A N/A

See Also

Summary
7XB intrinsic value, competitors valuation, and company profile.
DCF Valuation
7XB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
7XB stock valuation using valuation multiples.
Wall Street Estimates
7XB price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
7XB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 309,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.